Share on LinkedInShare on LinkedIn

ARTICLE · 03 MAY 2024

Developments In Securities Fraud Class Actions Against U.S. Life Sciences Companies

Dechert
Dechert
Contributor
Dechert

Dechert

Dechert helps business leaders lead For more than 150 years, we’ve advised the innovators who move...

View firm profile
Explore more from Dechert

Last year marked an increase in federal securities class action filings, with plaintiffs filing 213 cases in 2023, up from 197 in 2022 and ending an overall decline in filings since 2019.

United StatesLitigation, Mediation & Arbitration

Last year marked an increase in federal securities class action filings, with plaintiffs filing 213 cases in 2023, up from 197 in 2022 and ending an overall decline in filings since 2019. Life sciences companies remained popular targets, accounting for approximately one in five of these filings.1In this white paper, we examine 2023's filing and decision trends, providing insights for life sciences companies to prudently navigate the litigation landscape.

READ THE FULL REPORT

1460230a.jpg

Plaintiffs filed a total of 43 securities class action lawsuits against life sciences companies in 2023, which represented almost one in five securities class action lawsuits.

Filings against life sciences companies in 2023 remained stable from the previous year but represent an approximately 50% decrease from five years prior in 2018.Of these cases, the following trends emerged:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from